1. Plasma metabolomics and clinical predictors of survival differences in COPD patients
- Author
-
Victor Pinto-Plata, Ciro Casanova, Miguel Divo, Yohannes Tesfaigzi, Vince Calhoun, Jing Sui, Francesca Polverino, Carmen Priolo, Hans Petersen, Juan Pablo de Torres, Jose Maria Marin, Caroline A. Owen, Rebeca Baz, Elizabeth Cordova, and Bartolome Celli
- Subjects
COPD ,Metabolomics ,Survival ,Dyspnea ,Exercise capacity ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background Plasma metabolomics profile (PMP) in COPD has been associated with clinical characteristics, but PMP’s relationship to survival has not been reported. We determined PMP differences between patients with COPD who died an average of 2 years after enrollment (Non-survivors, NS) compared to those who survived (S) and also with age matched controls (C). Methods We studied prospectively 90 patients with severe COPD and 30 controls. NS were divided in discovery and validation cohorts (30 patients each) and the results compared to the PMP of 30 S and C. All participants completed lung function tests, dyspnea scores, quality of life, exercise capacity, BODE index, and plasma metabolomics by liquid and gas chromatography / mass spectometry (LC/MS, LC/MS2, GC/MS). Statistically, we used Random Forest Analysis (RFA) and Support Vector Machine (SVM) to determine metabolites that differentiated the 3 groups and compared the ability of metabolites vs. clinical characteristics to classify patients into survivors and non-survivors. Results There were 79 metabolites statistically different between S and NS [p
- Published
- 2019
- Full Text
- View/download PDF